[1] |
WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang.
Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases
[J]. China Oncology, 2024, 34(6): 527-536.
|
[2] |
TANG Duocai, ZHOU Shukui, ZHANG Guiyin, LIU Lei, LIAO Hong.
Analysis of risk factors of recurrence in non-muscle invasive bladder cancer patients after initial transurethral resection of bladder tumor
[J]. China Oncology, 2023, 33(5): 478-483.
|
[3] |
DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong.
Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer
[J]. China Oncology, 2023, 33(3): 267-273.
|
[4] |
CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong.
Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer
[J]. China Oncology, 2022, 32(7): 588-595.
|
[5] |
QI Mengfang, TIAN Tian, HUANG Rui.
Clinicopathological characteristics and 131I treatment of differentiated thyroid carcinoma in children and adolescents of different age groups
[J]. China Oncology, 2022, 32(5): 404-409.
|
[6] |
GUO Wenting, MU Zhuanzhuan, LI Zheng, ZHANG Yingqiang, JIN Xiaona, LIN Yansong.
Clinical outcome of 131I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration
[J]. China Oncology, 2022, 32(5): 410-416.
|
[7] |
Expert Committee of Nuclear Medicine, Chinese society of Clinical Oncology, Expert Committee of Thyroid Cancer, Chinese society of Clinical Oncology, Committee of Thyroid Disease Society, China International Exchange and Promotive Association for Medical and Health Care, Committee of Thyroid Disease Prevention and Treatment Society, China Population Culture Promotion Association.
Expert consensus on management of differentiated thyroid carcinoma in children and adolescents (2022 edition)
[J]. China Oncology, 2022, 32(5): 451-468.
|
[8] |
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong.
Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers
[J]. China Oncology, 2022, 32(12): 1147-1157.
|
[9] |
ZHAO Mingming, WANG Tianyou, WANG Chao.
Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer
[J]. China Oncology, 2022, 32(11): 1098-1104.
|
[10] |
LIN Yi, WANG Ce, KANG Xun, KANG Zhuang, CHEN Feng, JIANG Bo, LI Wenbin.
Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis
[J]. China Oncology, 2022, 32(1): 13-23.
|
[11] |
LI Zeng , WU Yi , CHEN Zhuzhong , CHEN Li , LIAO Hong , MAO Dun , XIAO Yingming , XIE Hongping , LI Xiuli , YANG Shengke , ZHOU Shukui , ZHONG Lei , LU Hao , CHEN Yongji .
The value of 18 F-PSMA-1007 PET/CT in the early diagnosis and clinical treatment of patients with biochemical recurrence after radical prostatectomy
[J]. China Oncology, 2021, 31(11): 1081-1087.
|
[12] |
LU Xiaoteng, XU Qing.
A study on factors associated with recurrence of non-small cell lung cancer based on CT image features
[J]. China Oncology, 2020, 30(8): 636-640.
|
[13] |
CHEN Yang , LIU Wei , LI Ruimin , WANG Qifeng , SHEN Xigang , TANG Wei .
Radiogenomics: association between BI-RADS mammographic imaging features and the 21-gene recurrence score
[J]. China Oncology, 2020, 30(7): 505-511.
|
[14] |
FENG Zheng, WU Xiaohua.
Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer
[J]. China Oncology, 2020, 30(4): 299-304.
|
[15] |
GAO Luying, LIN Yansong, JIANG Yuxin, LI Jianchu, LI Hui, ZHANG Bo, LIU Ruyu, XI Xuehua, GAO Qiong, WANG Ying, ZHAO Ruina.
Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2019, 29(6): 418-422.
|